TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:21
Acurx Pharmaceuticals Inc. ( ACXP ) https://www.acurxpharma.com
0.90USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-77.33%
ACXP
SPY
32.66%
-81.01%
ACXP
SPY
108.59%
ACXP
0.00%
SPY
302.52%
ACXP
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
14.32
-5748.25
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.87
0.00
5.37
-20.37
0.00
-2210.48
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-0.48
-236.08
0.00
Other Earnings and Cash Flow Stats:
Acurx Pharmaceuticals Inc. ( ACXP ) Net Income TTM ($MM) is -16.44
Acurx Pharmaceuticals Inc. ( ACXP ) Operating Income TTM ($MM) is -16.44
Acurx Pharmaceuticals Inc. ( ACXP ) Owners' Earnings Annual ($MM) is 0.00
Acurx Pharmaceuticals Inc. ( ACXP ) Current Price to Owners' Earnings ratio is 0.00
Acurx Pharmaceuticals Inc. ( ACXP ) EBITDA TTM ($MM) is 1.30
Acurx Pharmaceuticals Inc. ( ACXP ) EBITDA Margin is 0.00%
Capital Allocation:
Acurx Pharmaceuticals Inc. ( ACXP ) has paid 0.00 dividends per share and bought back -3.358345 million shares in the past 12 months
Acurx Pharmaceuticals Inc. ( ACXP ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Acurx Pharmaceuticals Inc. ( ACXP ) Interest-bearing Debt ($MM) as of last quarter is 0
Acurx Pharmaceuticals Inc. ( ACXP ) Annual Working Capital Investments ($MM) are -3316
Acurx Pharmaceuticals Inc. ( ACXP ) Book Value ($MM) as of last quarter is 2
Acurx Pharmaceuticals Inc. ( ACXP ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Acurx Pharmaceuticals Inc. ( ACXP ) has 5 million in cash on hand as of last quarter
Acurx Pharmaceuticals Inc. ( ACXP ) has 3 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Acurx Pharmaceuticals Inc. ( ACXP ) has 16 common shares outstanding as of last quarter
Acurx Pharmaceuticals Inc. ( ACXP ) has 0 million USD of preferred stock value
Academic Scores:
Acurx Pharmaceuticals Inc. ( ACXP ) Altman Z-Score is -19.78 as of last quarter
Acurx Pharmaceuticals Inc. ( ACXP ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Acurx Pharmaceuticals Inc. ( ACXP ) largest shareholder is owning shares at 0.00 ($MM) value
Carl Sailer(an insider) Bought 19737 shares of Acurx Pharmaceuticals Inc. ( ACXP ) for the amount of $75000.60 on 2022-07-27
14.80% of Acurx Pharmaceuticals Inc. ( ACXP ) is held by insiders, and 11.96% is held by institutions
Acurx Pharmaceuticals Inc. ( ACXP ) went public on 2021-06-25
Other Acurx Pharmaceuticals Inc. ( ACXP ) financial metrics:
FCF:-12.33
Unlevered Free Cash Flow:0.00
EPS:-0.69
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-423.66
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Acurx Pharmaceuticals Inc. ( ACXP ) :
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.